ArticleGastroenterology & hepatology2025
Enhancing the Diagnostic Yield of EGD for Diagnosis of Barrett Esophagus Through Methylated DNA Biomarker Triage.
Article in Gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsoGuard (EG) is a methylated DNA assay for cells collected nonendoscopically with EsoCheck for detection of Barrett esophagus (BE) and can be utilized as a triage to esophagogastroduodenoscopy (EGD) in patients meeting clinical criteria for BE screening. EG triage may enrich the population undergoing EGD, increasing BE diagnosis without overburdening endoscopy resources.
aimTo test the hypothesis that EGDs performed on patients who test positive on EG have higher diagnostic yields than screening EGDs alone.
methodsWe collected real-world retrospective data from EG-positive patients for whom EGD diagnoses were available. The diagnostic yield of these EGDs was measured by the BE detection rate. The yield of screening EGDs was estimated by literature-established disease prevalence (10.6%). The hypothesis was tested using t-test for single proportions at a one-sided 5% significance level.
resultsAmong 209 patients, 60 (28.7%) had specialized intestinal metaplasia but 10 (4.8%) had less than 1 cm of nondysplastic disease. Because the American College of Gastroenterology (ACG) definition of BE requires disease length of at least 1 cm, these patients were excluded from analysis. In the analyzed population, we observed a 2.4-fold increase in BE detection compared with the 10.6% performance goal. There was a 2.7-fold increase in the cohort meeting ACG screening criteria and a 2.5-fold increase among those meeting ACG criteria who were aged 65 years and older.
conclusionEG triage enriches the population undergoing EGD for BE detection. Compared with screening EGD alone, it improves diagnostic yield. This may help direct more efficient use of endoscopy resources to improve disease detection in at-risk patients.
Indexed as
Identifiers
40416302PMC12100536What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.